newsfilter
← Latest News
Business Wire·

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

— CTA Approvals Received for RLYB212 Phase 2 Clinical Trial; On Track to Initiate Screening in 4Q 2024 — — $75.1 Million in Cash, Cash Equivalents, and Marketable Securities as of September 30, 2024 Provides Runway